Dyne Therapeutics, Inc. 4

Catherine Stehman-Breen received an option award for 35,152 shares of Dyne Therapeutics, Inc. common stock at a $17.04 exercise price.

On June 5, 2026, Catherine Stehman-Breen received a stock option grant from Dyne Therapeutics, Inc. covering 35,152 shares of common stock at an exercise price of $17.04 per share, with no cash paid at grant. This option, which expires on June 4, 2036, will vest in full on the earlier of June 5, 2027 or the date of Dyne’s 2027 Annual Meeting of Stockholders, subject to her continued service. Following this award, she beneficially owns 35,152 shares (on an option-as-converted basis) in a direct capacity, representing a routine equity compensation grant rather than an open-market purchase or sale.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001193125-26-264011

Alert Tier

5